Standout Papers

Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A 2023 2026 202491
  1. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A (2023)
    Annette von Drygalski, Pratima Chowdary et al. New England Journal of Medicine

Immediate Impact

58 standout
Sub-graph 1 of 23

Citing Papers

The landscape of nanoparticle-based siRNA delivery and therapeutic development
2024 Standout
Chemically Modified Platforms for Better RNA Therapeutics
2024 Standout

Works of Stacey Poloskey being referenced

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
2023
Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)
2021

Author Peers

Author Last Decade Papers Cites
Stacey Poloskey 303 103 49 61 17 527
Courtney Byam 232 208 33 108 14 460
Jean-François Vanbellinghen 136 144 65 153 17 531
J. P. M. Evans 214 82 21 202 14 529
Xin Gao 273 200 12 133 15 543
Miriam Entesarian 94 292 41 64 15 612
Guido Kobbe 290 135 13 106 24 536
Björn Jacobsson 211 156 13 105 14 466
Galit Rozenfeld-Granot 214 159 8 90 11 471
Matthew Devine 238 135 128 269 14 519
Wendy Schaffer 113 196 32 40 12 625

All Works

Loading papers...

Rankless by CCL
2026